Act Two Investors LLC Buys 532 Shares of Stryker Co. (NYSE:SYK)

Act Two Investors LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 3.1% during the fourth quarter, HoldingsChannel reports. The firm owned 17,684 shares of the medical technology company’s stock after purchasing an additional 532 shares during the quarter. Stryker accounts for approximately 1.1% of Act Two Investors LLC’s holdings, making the stock its 19th biggest position. Act Two Investors LLC’s holdings in Stryker were worth $5,296,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Private Advisor Group LLC lifted its position in Stryker by 1.7% during the 3rd quarter. Private Advisor Group LLC now owns 13,434 shares of the medical technology company’s stock valued at $3,670,000 after acquiring an additional 229 shares during the period. NBC Securities Inc. purchased a new position in Stryker during the 3rd quarter valued at about $541,000. Lincoln National Corp lifted its position in Stryker by 1.6% during the 3rd quarter. Lincoln National Corp now owns 7,054 shares of the medical technology company’s stock valued at $1,928,000 after acquiring an additional 112 shares during the period. Picton Mahoney Asset Management lifted its position in Stryker by 20.5% during the 3rd quarter. Picton Mahoney Asset Management now owns 1,030 shares of the medical technology company’s stock valued at $282,000 after acquiring an additional 175 shares during the period. Finally, Childress Capital Advisors LLC purchased a new position in Stryker during the 3rd quarter valued at about $290,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock traded up $5.42 during trading hours on Friday, reaching $335.54. The company had a trading volume of 1,230,572 shares, compared to its average volume of 1,514,076. The business has a fifty day moving average price of $339.85 and a 200-day moving average price of $324.18. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The firm has a market cap of $127.82 billion, a PE ratio of 38.30, a price-to-earnings-growth ratio of 2.64 and a beta of 0.91. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. During the same period in the previous year, the business posted $2.14 earnings per share. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. Sell-side analysts predict that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 annualized dividend and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SYK. Wells Fargo & Company lifted their price target on shares of Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Roth Mkm lifted their target price on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. BTIG Research lifted their target price on shares of Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Citigroup lifted their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, UBS Group lifted their target price on shares of Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.50.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.